91113
document
The effect of valaciclovir on cytomegalovirus viremia and viruria detected by polymerase chain reaction in patients with advanced human immunodeficiency virus disease . AIDS Clinical Trials Group Protocol 204/Glaxo Wellcome 123-014 International CMV Prophylaxis Study Group . Samples of blood and urine were collected at baseline , week 4 , and week 8 and then every 8 weeks from 310 patients entering a controlled trial of prophylaxis with valaciclovir versus acyclovir . Samples were tested under code by polymerase chain reaction ( PCR ) in one laboratory . The median number of samples collected from each patient was 5 for blood ( range , 0-15 ) and 5 for urine ( range , 0-15 ) . Both baseline PCR viremia and PCR viruria were significantly associated with future cytomegalovirus ( CMV ) disease ( P = .002 and P = .02 , respectively ) . The greatest effect of valaciclovir on CMV disease was seen in patients who were PCR-positive in blood at baseline ( P = .002 ) , although a significant effect was also seen in those who were PCR-negative in urine ( P = .02 ) . Thus , PCR viremia provides prognostic information about CMV disease in AIDS patients , and valaciclovir showed activity as both a preemptive and prophylactic agent .
91114
Intervention_Pharmacological
valaciclovir
91115
Intervention_Pharmacological
prophylaxis
91116
Intervention_Pharmacological
valaciclovir
91117
Intervention_Pharmacological
acyclovir
91118
Intervention_Pharmacological
valaciclovir
91119
Intervention_Pharmacological
valaciclovir
91120
Outcome_Physical
cytomegalovirus viremia
91121
Outcome_Physical
number of samples
91122
Outcome_Physical
PCR viremia and PCR viruria
91123
Outcome_Physical
CMV
91124
Outcome_Physical
PCR viremia
91125
Participant_Condition
advanced human immunodeficiency virus disease
91126
Participant_Condition
310